CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCVRX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļCVRx Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 30, 2021
āļāļĩāļāļĩāđāļHykes (Kevin)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ206
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 30
āļāļĩāđāļāļĒāļđāđ9201 West Broadway Avenue
āđāļĄāļ·āļāļMINNEAPOLIS
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ55445
āđāļāļĢāļĻāļąāļāļāđ17634162850
āđāļ§āđāļāđāļāļāđhttps://www.cvrx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļCVRX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 30, 2021
āļāļĩāļāļĩāđāļHykes (Kevin)
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
Mr. Brent Binkowski
Chief Operating Officer
Mr. Jared Oasheim
Chief Financial Officer
Ms. Martha Shadan
Independent Director
Dr. Mudit K. Jain, Ph.D.
Independent Director
Dr. Philip B. Adamson
Chief Medical Officer
Mr. Kevin Ballinger
Independent Director
Mr. Kirk Nielsen
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
Mr. Brent Binkowski
Chief Operating Officer
Mr. Jared Oasheim
Chief Financial Officer
Ms. Martha Shadan
Independent Director
Proshares Ultra Russell 2000
ProShares UltraPro Russell2000
iShares Russell 2000 Growth ETF
Global X Russell 2000 ETF
ProShares Hedge Replication ETF
JPMorgan Fundamental Data Science Small Core ETF
iShares Russell 2000 Value ETF
Avantis US Small Cap Equity ETF
Goldman Sachs ActiveBeta US Small Cap Equity ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
iShares Micro-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.03%
Proshares Ultra Russell 2000
āļŠāļąāļāļŠāđāļ§āļ0.01%
ProShares UltraPro Russell2000
āļŠāļąāļāļŠāđāļ§āļ0.01%
iShares Russell 2000 Growth ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
Global X Russell 2000 ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
ProShares Hedge Replication ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
JPMorgan Fundamental Data Science Small Core ETF
iShares Russell 2000 Value ETF
Avantis US Small Cap Equity ETF
Goldman Sachs ActiveBeta US Small Cap Equity ETF
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ